Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph U Correll

Showing results (61-70 of 1,042) with videos related to

Pageof 105
Sort By:
The Journal of Clinical Psychiatry|June 26, 2009
Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening needDan Cohen, Christoph U Correll
Expert Review of Clinical Pharmacology|April 29, 2015
Glutamatergic agents for schizophrenia: current evidence and perspectivesMathias Zink, Christoph U Correll
Acta Psychiatrica Scandinavica|October 30, 2010
Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed?Christoph U Correll, Jimmi Nielsen
Expert Review of Neurotherapeutics|July 1, 2010
Management of antipsychotic-related weight gainLawrence Maayan, Christoph U Correll
The Journal of Clinical Psychiatry|February 3, 2025
Relationship Between Trauma, PTSD, and Schizophrenia: Relevance for Outcomes, Screening, and InterventionsJulieta Ramirez, Christoph U Correll
Frontiers in Psychiatry|June 19, 2023
Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publicationsAnuradha Baminiwatta, Christoph U Correll
The Journal of Clinical Psychiatry|July 2, 2020
Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in SchizophreniaChristoph U Correll, John Lauriello
Dialogues in Clinical Neuroscience|October 20, 2010
Pharmacologic treatment of schizophreniaJohn M Kane, Christoph U Correll
The Journal of Clinical Psychiatry|June 20, 2020
Drs Kane and Correll ReplyJohn M Kane, Christoph U Correll
JAMA Psychiatry|June 25, 2020
Management of Patients With Severe Mental Illness During the Coronavirus Disease 2019 PandemicKai G Kahl, Christoph U Correll
Pageof 105

Showing results (61-70 of 1,042) with videos related to

Sort By:
Pageof 105
The Journal of Clinical Psychiatry|June 26, 2009
Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening needDan Cohen, Christoph U Correll
Expert Review of Clinical Pharmacology|April 29, 2015
Glutamatergic agents for schizophrenia: current evidence and perspectivesMathias Zink, Christoph U Correll
Acta Psychiatrica Scandinavica|October 30, 2010
Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed?Christoph U Correll, Jimmi Nielsen
Expert Review of Neurotherapeutics|July 1, 2010
Management of antipsychotic-related weight gainLawrence Maayan, Christoph U Correll
The Journal of Clinical Psychiatry|February 3, 2025
Relationship Between Trauma, PTSD, and Schizophrenia: Relevance for Outcomes, Screening, and InterventionsJulieta Ramirez, Christoph U Correll
Frontiers in Psychiatry|June 19, 2023
Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publicationsAnuradha Baminiwatta, Christoph U Correll
The Journal of Clinical Psychiatry|July 2, 2020
Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in SchizophreniaChristoph U Correll, John Lauriello
Dialogues in Clinical Neuroscience|October 20, 2010
Pharmacologic treatment of schizophreniaJohn M Kane, Christoph U Correll
The Journal of Clinical Psychiatry|June 20, 2020
Drs Kane and Correll ReplyJohn M Kane, Christoph U Correll
JAMA Psychiatry|June 25, 2020
Management of Patients With Severe Mental Illness During the Coronavirus Disease 2019 PandemicKai G Kahl, Christoph U Correll
Pageof 105